Long-term favorable results by arteriovenous graft with Omniflow II prosthesis for hemodialysis.
OBJECTIVE
In order to decrease arteriovenous graft (AVG) failure and improve long-term patency, we used Omniflow II to perform AVG for hemodialysis access in 38 patients with very compromised vessels who were not suitable for other forms of AVG.


RESULTS
At a median follow-up of 38 (range 6-55) months, 31/38 (81%) patients were still alive. At 6, 12, 18 and 24 months, the primary patency was 83, 80, 68 and 60%, whereas the secondary patency was 92, 83, 78 and 75%,respectively [corrected].The cumulative 38-month prosthetic AVG patency was 70%. No infective event related to the vascular prosthesis occurred. Neither AVG thrombosis nor modifications in thrombophilic pattern were observed; these findings confirm the high hemocompatibility of this prosthetic vascular device.


CONCLUSIONS
Our experience is extremely encouraging for the use of new biosynthetic devices such as Omniflow II.
Palumbo
Roberto
R
Nephrology Unit , S. Eugenio Hospital, Tor Vergata University, Rome, Italy. palumbo.dr@gmail.com
Niscola
Pasquale
P
Calabria
Santo
S
Fierimonte
Sabrina
S
Bevilacqua
Monica
M
Scaramucci
Laura
L
Tolu
Barbara
B
de Fabritiis
Paolo
P
Bondanini
Francesco
F
D000328:Adult; D000368:Aged; D000714:Anastomosis, Surgical / Q000295:instrumentation*; D001807:Blood Vessel Prosthesis; D019544:Equipment Failure Analysis; D005260:Female; D006440:Hemofiltration / Q000295:instrumentation*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000534:rehabilitation* / Q000601:surgery*; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome